| 0.8411 -0.189 (-18.34%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.32 |
1-year : | 1.53 |
| Resists | First : | 1.13 |
Second : | 1.3 |
| Pivot price | 1.09 |
|||
| Supports | First : | 0.84 |
Second : | 0.69 |
| MAs | MA(5) : | 1 |
MA(20) : | 1.11 |
| MA(100) : | 3 |
MA(250) : | 9.3 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 4.4 |
D(3) : | 10 |
| RSI | RSI(14): 23.4 |
|||
| 52-week | High : | 24.29 | Low : | 0.84 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SBFM ] has closed below the lower bollinger band by 21.3%. Bollinger Bands are 83.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 63 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.01 - 1.02 | 1.02 - 1.02 |
| Low: | 0.83 - 0.84 | 0.84 - 0.84 |
| Close: | 0.83 - 0.84 | 0.84 - 0.85 |
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Wed, 16 Sep 2026
An oral drug candidate suppressed lung virus in infected mice - Stock Titan
Wed, 16 Sep 2026
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies - Yahoo Finance
Fri, 28 Aug 2026
Sunshine Biopharma (NASDAQ: SBFM) could raise $31M from warrants - Stock Titan
Sun, 09 Aug 2026
SBFM Stock Holds Support As Traders Eye Next Move - timothysykes.com
Fri, 07 Aug 2026
SBFM Stock Slides As Traders Focus On Cash Runway And Volatility - StocksToTrade
Thu, 25 Jun 2026
SBFM Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 7.1 (%) |
| Shares Short | 74 (K) |
| Shares Short P.Month | 62 (K) |
| EPS | -9.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.52 |
| Profit Margin | -16.5 % |
| Operating Margin | -17.5 % |
| Return on Assets (ttm) | -10 % |
| Return on Equity (ttm) | -22 % |
| Qtrly Rev. Growth | -1.7 % |
| Gross Profit (p.s.) | 2.76 |
| Sales Per Share | 9.11 |
| EBITDA (p.s.) | -1.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.07 |
| Price to Sales | 0.09 |
| Price to Cash Flow | -0.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|